Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAPK10
REST API REST API
Homo sapiens
MAPK10 is differentially expressed in 206 experiments: 153 organism parts: amygdala, liver, ... (151 more);, 163 disease states: normal, glioblastoma, ... (161 more);, 55 cell types 255 cell lines 22 compound treatments and 60 other conditions.
Synonyms PRKM10, p54bSAPK, p493F12, JNK3
Orthologs HOG1 (Saccharomyces cerevisiae)   Q4H3A2_CIOIN (Ciona intestinalis)   MAPK10 (Gallus gallus)   Mapk10 (Mus musculus)   mapk8b (Danio rerio)   mapk10 (Danio rerio)   mapk8a (Danio rerio)   mapk9 (Danio rerio)   A4FV00_BOVIN (Bos taurus)   Mapk10 (Rattus norvegicus)   mapk10 (Xenopus laevis)   MAPK10 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Toll signaling pathway, cytosol, plasma membrane, JUN kinase activity, protein binding, phosphotransferase activity, alcohol group as acceptor, JUN phosphorylation, cytoplasm, innate immune response, membrane, protein tyrosine kinase activity, MAP kinase kinase activity, stress-activated MAPK cascade, MAP kinase activity, ATP binding, transferase activity, transferring phosphorus-containing groups, nucleotide binding, protein serine/threonine kinase activity, JNK cascade, nucleoplasm, signal transduction, lipopolysaccharide biosynthetic process, protein kinase activity, mitochondrion, toll-like receptor 4 signaling pathway, toll-like receptor signaling pathway, toll-like receptor 3 signaling pathway, toll-like receptor 2 signaling pathway, MyD88-dependent toll-like receptor signaling pathway, protein phosphorylation, MyD88-independent toll-like receptor signaling pathway, regulation of sequence-specific DNA binding transcription factor activity, toll-like receptor 1 signaling pathway
InterPro Term Prot_kinase_cat_dom, JNK_MAPK, LipoPS_kinase, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
Gene-Disease Assocation EPILEPTIC ENCEPHALOPATHY, LENNOX-GASTAUT TYPE
UniProt Accession D6R9C1, Q499Y8, A8MPV1, D6RDG1, D6RC26, D6RCB1, D6RAJ0, D6RAU3, D6RBH2, D6RFX8, D6RFZ7, D6RJF9, A8MWW6, P53779, B7Z1Z1, A6NG28, B3KR72, A8MWR3
Search EB-eye ENSG00000109339
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (25 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
BT-474
2
E-GEOD-3529, E-GEOD-5823
SW480
2
E-MEXP-1014, E-MTAB-37
NCIH2052
1
E-MTAB-37
H4
1
E-MTAB-37
249 more value(s).


Cell type

studied in E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-GEOD-13909, E-GEOD-13987, ... (29 experiments)

Factor Value U/D Experiments
stromal cell
2
E-MEXP-2034, E-GEOD-3998
bronchial epithelial
1
E-MTAB-25
centroblast
1
E-TABM-702
B lymphocyte
1
E-GEOD-6691
adherent cell
1
E-MEXP-551
astrocyte
1
E-GEOD-4483
49 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1121, E-GEOD-16363, E-GEOD-3678, E-MTAB-62, ... (54 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-20295, E-GEOD-3185
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-1880
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
myxoid liposarcoma
2
E-MTAB-62, E-GEOD-6481
157 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-5258, E-GEOD-5824, E-TABM-868, E-MEXP-2645, ... (15 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
17beta-estradiol
4
1
E-GEOD-4006
disease modifying antirheumatic drugs, non-steroidal anti-inflammatory drugs, steroids
1
E-GEOD-1919
4,5-dianilinophthalimide
1
1
E-GEOD-5258
Cxcl12
1
1
E-GEOD-7307
ethanol
1
E-MEXP-2241
16 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-19246, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-3325, E-GEOD-1561, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-MEXP-421, E-TABM-321, E-GEOD-18736, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-MEXP-1446, E-MEXP-1741, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-MEXP-1648, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-1309, E-GEOD-21750

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.321 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM